Adlaon, Kyle .
HRN: 26-25-86 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
11/22/2024
CEFOTAXIME 500MG (VIAL)
11/22/2024
11/28/2024
IV
180 Mg
Q8H
Neonatal Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes